SCHEMBL700877

SCHEMBL700877

CN1CCC(CNc2cncc(-c3ccc(C=C4C(=O)Nc5ccc(Cl)cc54)o3)n2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 8/20 0.62
PIM2 Q9P1W9 7/20 0.62
CCNT1 O60563 1/20 0.49
FLT3 P36888 3/20 0.48
PIM3 Q86V86 1/20 0.48
PTPN1 P18031 5/20 0.42
PTPN2 P17706 1/20 0.42
PDGFRB P09619 1/20 0.40
FGFR1 P11362 1/20 0.40
KDR P35968 1/20 0.40
RPS6KA3 P51812 1/20 0.40
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
PPARG P37231 1/20 0.38
KMT2A Q03164 1/20 0.38
NCOA2 Q15596 1/20 0.38
NCOA1 Q15788 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10091751 1.00 PIM1 (0.62) PIM1PIM2CCNT1FLT3PIM3
SCHEMBL700875 1.00 PIM1 (0.62) PIM1PIM2CCNT1FLT3PIM3
SCHEMBL700876 0.82 PIM1 (0.62) PIM1PIM2FLT3PIM3PTPN1
SCHEMBL704231 0.79 PIM2 (0.74) PIM1PIM2FLT3PIM3PTPN1
SCHEMBL704232 0.79 PIM2 (0.74) PIM1PIM2FLT3PIM3PTPN1
SCHEMBL703105 0.78 PIM1 (0.61) PIM1PIM2FLT3PIM3PTPN1
SCHEMBL703106 0.78 PIM1 (0.61) PIM1PIM2FLT3PIM3PTPN1
SCHEMBL31434337 0.76 PIM1 (0.74) PIM1PIM2FLT3PIM3PDGFRB
SCHEMBL10091728 0.72 PIM1 (0.59) PIM1PIM2FLT3PIM3PTPN1
SCHEMBL10091659 0.72 PIM1 (0.58) PIM1PIM2FLT3PIM3PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885PIM2 3/4885CCNT1 608/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885PIM2 3/4885CCNT1 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.